01 / Antibody intelligence, made actionable

Validation
starts in the tissue.

Monoclonal research antibodies for researchers, pathologists and biomarker teams who need evidence they can inspect.

Fluorescence multiplex immunohistochemistry of a normal human tonsil with anti-CD8 (DIA-TC8; orange/red) and anti-CD112R/PVRIG clone R12 (DIA-R12; green), nuclei blue – overlay with detail inset

CD8 × CD112R multiplexHuman tonsil · Clones TC8 + R12 · Fluorescence IHC

Developed with histopathologyONCOdianova is an antibody manufacturing network linking antibody development to histopathological validation.
Tissue-profiledOur antibodies have been tested on many different tumor and normal tissues.
Validated by pathologistsOur clones have been validated by pathologists from routine diagnostic laboratories.
Published evidenceClone-specific peer-reviewed use, cited with DOI where available.
Multiplex IHCDocumented in multiplex settings for selected clones.

For Research Use Only. Not for use in diagnostic procedures.

Find the right signal.

Seven monoclonal clones for tissue-based immuno-oncology research — searchable by target, clone and application.

7 clones · RUO

What these clones made possible.

The following antibody highlights from ONCOdianova are documented in peer-reviewed tissue-based research:

  1. TIGIT

    Clone TG1 · DIA-TG1-M

    TIGIT is one of the most important checkpoint markers for the development of new immunotherapies against cancer. The TG1 evidence base comprises twelve peer-reviewed IHC references plus one separately presented peer-reviewed Imaging Mass Cytometry publication.

    New application evidenceTG1 in highly multiplexed Imaging Mass Cytometry

    Product page
  2. PVRIG / CD112R

    Clone R12 · DIA-R12

    PVRIG / CD112R plays an important role in the development of effective combination therapies with PD1 and TIGIT. Clone R12 was used in a peer-reviewed four-marker fluorescence multiplex IHC study of a cohort of 523 colorectal cancers.

    Product page

Explore the new anti-TIGIT clone TG2 now with higher staining intensity.

Explore TG2

Our strong feedback from laboratories applying the new ONCOdianova antibodies against CD112R, TIGIT and CALRmut shows that they are perceived as innovative tools for immunohistochemistry, because they allow new approaches for tissue based studies of important biomarkers.

Four pillars. One standard.

ONCOdianova is an antibody manufacturing network focused on research antibodies for human FFPE IHC and fluorescence multiplex applications. In multiplex IHC, several markers are examined in parallel under coordinated staining conditions. ONCOdianova combines hybridoma development with histopathological evaluation in human tissue research.

For Research Use Only. Not for use in diagnostic procedures.

ONCOdianova icon: antibody symbol

Develop

Our idea is to integrate immunohistochemistry as early as possible in the hybridoma screening procedure and thereby expand the classical ELISA screen by histopathological expertise at an early stage of FFPE antibody development.

ONCOdianova icon: tissue cells

Validate

We use our strong network for histopathological validation of new targets in human tissues. This expands our expertise to develop new test systems for novel targets. For cancer immunology targets we put a focus on tumor infiltrating lymphocytes.

ONCOdianova icon: rising curve

Improve

Multiplex Assay technology develops fast and depends on the availability of reliable antibody reagents. Our vision is to provide documented cancer-immunology research antibodies for combined use in tissue-based studies.

ONCOdianova icon: handshake

Partner

Our objective is to potentially develop multiple clones for the same target by approaching one target at diverse immunogenic sites. We are able to reference mapped epitopes and open for beta testing opportunities with pharmaceutical partners.

A method you can
inspect.

Every product page documents peer-reviewed clone-specific evidence, congress abstracts and technical specifications, with references, catalog numbers and RRIDs where assigned.

Evidence layer 01

Clone selection

Context-led clone evaluation with immunohistochemistry integrated early in development.

Evidence layer 02

Pattern profiling

Pattern assessment across human normal and tumor tissues with defined positive controls.

Evidence layer 03

Published evidence

Clone-specific use documented in peer-reviewed studies where available — each cited with DOI on the product page.

Fluorescence multiplex immunohistochemistry of a normal human tonsil with anti-CD8 (DIA-TC8; orange/red) and anti-CD112R/PVRIG clone R12 (DIA-R12; green), nuclei blue – overlay with detail inset
Designed for the question

From marker
to meaning.

Products are organised around the questions research teams actually ask: immune phenotype, checkpoint axes, spatial arrangement and tumour context.

  • Immuno-oncology markers
  • Multiplex IHC panels
  • FFPE tissue research

CD8 × CD112R multiplex · Human tonsil · Clones TC8 + R12

Clear pathways for
every next step.

Orders are handled through BIOZOL Diagnostica Vertrieb GmbH. Every route maps a specialist question to a product, a document or a conversation.

For Research Use Only. Not for use in diagnostic procedures.